How Med Spas Actually Make Money

A medical spa is a business with two faces. One face looks like a clinic: licensed clinicians, medical protocols, regulated devices and professional liability. The other face looks like a wellness retailer: product shelves, membership tiers, seasonal promotions and lifetime-value calculations.

The economics sit in the overlap. Injectables produce the highest margins. Retail products and membership fees produce recurring revenue. Private-equity-backed rollups produce valuation multiples that individual clinics cannot match. Each revenue stream behaves differently in terms of gross margin, patient retention and capital intensity, and the mix a clinic chooses determines its financial profile more than its location or patient volume.

This article examines how US med spas generate revenue, what each stream costs to deliver, and how consolidation and alternative business models are reshaping the industry's economics. It is a structural survey, not a financial projection or a recommendation for any specific business.

Where the revenue comes from

Industry estimates consistently describe a similar revenue split for a mature, multi-service US medical spa. Based on practice-management surveys and operator-reported data compiled by the American Med Spa Association (AmSpa) in its 2024 State of the Industry Report, the largest single revenue category is aesthetic injectables. The same AmSpa report is the source most commonly cited by industry media for aggregate revenue-breakdown figures, though AmSpa notes that its survey sample skews toward member clinics and may overrepresent established operators.

The approximate distribution reported across surveyed clinics:

• Aesthetic injectables (neuromodulators and fillers): 45–60% of revenue.
• Energy-based devices (laser, IPL, radiofrequency, microneedling): 15–25% of revenue.
• Retail skin-care and cosmeceutical products: 10–20% of revenue.
• Membership or subscription programs: 5–15% of revenue.
• Ancillary services (vitamin injections, IV therapy, body contouring, wellness): 5–10% of revenue.

These are survey-based ranges, not a single representative figure. Individual clinics can deviate substantially based on service mix, provider composition and local market conditions.

The short answer — United States, evidence checked July 17, 2026: Injectables contribute roughly half of med spa revenue and the majority of gross profit. Memberships and retail products add predictable recurring income. Private-equity-backed consolidation is the dominant structural force changing how revenue is captured and valued.

Injectables are the profit engine

Neuromodulators (onabotulinumtoxinA, incobotulinumtoxinA, abobotulinumtoxinA, daxibotulinumtoxinA) and dermal fillers (hyaluronic acid-based, calcium hydroxylapatite, poly-L-lactic acid, polymethyl methacrylate) are the highest-margin clinical service in almost every med spa. Gross margins for injectables are typically estimated at 70–80%, based on the spread between product acquisition cost and the per-unit or per-area price charged to the patient.

The mechanism is straightforward. A vial of onabotulinumtoxinA that costs the clinic $400–$600 can be split across multiple patients and billed at $10–$18 per unit, producing several thousand dollars in revenue per vial. Fillers purchased at $300–$600 per syringe are typically sold to patients at $600–$1,200 per syringe depending on product, market and provider experience.

What the gross margin does not capture: injectables require a licensed medical professional (physician, nurse practitioner, physician assistant or registered nurse under supervision depending on state law), medical liability insurance, consent processes, sharps disposal, cold-chain storage, and — in some states — a supervising physician who may receive a fee or percentage. These costs are substantially lower than the facility and equipment costs associated with energy-based devices, but they are not zero.

Patient retention in injectables follows a pharmacological schedule. Neuromodulators typically last 3–4 months, and hyaluronic acid fillers last 6–18 months depending on product and injection site. This built-in repeat cycle is the primary driver of retention economics: a patient who returns twice a year for neuromodulator treatments produces a predictable annual revenue stream without requiring a subscription or membership commitment.

The 2024 AmSpa State of the Industry Report estimates that the average injectables patient visits 2.8 times per year. At an average spend of $400–$700 per visit depending on units and products used, a retained injectables patient generates approximately $1,100–$1,960 in annual clinical revenue per patient — before retail or membership add-ons — at an estimated gross margin of 70–80%.

What margins actually mean for clinic economics

A 75% gross margin on $150,000 in injectables revenue leaves $112,500 to cover direct clinical costs and contribute toward rent, salaries, marketing, insurance and overhead. At a typical clinic overhead rate of 50–60% of total revenue (a range reported in practice-management benchmarks from AmSpa and from the American Med Spa Association), the net clinic margin after all operating expenses may settle in the 10–20% range for a well-run single-location clinic.

The spread between gross margin and net margin matters because it explains why volume and utilization are so important to clinic profitability. Fixed costs (rent, salaries, software) are relatively stable. Variable costs (product, disposables, commission) move with volume. A clinic that can increase patient volume without adding proportional fixed cost improves its net margin faster than its gross margin would suggest.

Energy-based devices: capital-heavy, margin-thinner

Lasers, intense pulsed light (IPL) devices, radiofrequency microneedling platforms, high-intensity focused ultrasound (HIFU) and cryolipolysis devices are a significant revenue line for many med spas. Unlike injectables, they carry substantial upfront capital cost. A new fractional CO2 laser or a multi-application radiofrequency platform can cost $60,000–$150,000 depending on manufacturer, features and whether it is purchased outright or leased.

Device margins are lower than injectables — typically estimated at 40–60% gross — because the revenue per treatment is priced to recover the equipment investment over 200–500 treatments. Per-treatment revenue varies by geography and device: laser hair removal sessions may be priced at $150–$400 per area, full-face fractional resurfacing at $800–$2,500 per session, and radiofrequency microneedling at $800–$2,000 per session.

The retention pattern for device-based treatments differs from injectables. Some protocols require a series (3–6 sessions for laser hair removal, 3–4 for microneedling), which creates a completion-based revenue stream rather than an indefinite repeat cycle. Once the series concludes, the patient may not return for that treatment for months or years. This makes device-based practices more dependent on new-patient acquisition for volume maintenance than injectables-heavy practices.

Device selection also carries a different risk profile. A device that becomes obsolete or that a competitor adopts with lower pricing can compress utilization and extend the payback period. Leasing shifts some risk to the financier but increases monthly fixed costs.

Retail products: lower margin, higher predictability

Retail cosmeceutical products — medical-grade cleansers, antioxidants, sunscreens, growth-factor serums and post-procedure care — serve a dual role in med spa economics. They generate direct revenue at gross margins of 40–55% depending on wholesale pricing and whether the clinic marks up to manufacturer suggested retail price (MSRP) or discounts for loyalty. More importantly, they extend the relationship between visits. A patient who purchases a $60 sunscreen and a $90 growth-factor serum between appointments has a transaction reason to return to the clinic, increasing touchpoints per year and reducing the likelihood of switching to a competitor.

The American Med Spa Association's benchmarking data suggests that retail penetration — the percentage of treatment patients who also purchase retail products — averages 30–40% among surveyed clinics. A clinic with 1,000 active patients and an average retail transaction of $100 per purchase, with 2.5 retail transactions per purchasing patient per year, produces approximately $75,000–$100,000 in annual retail revenue at a gross margin of roughly 50%.

Retail does not require clinician time, which means it does not compete with treatment scheduling capacity. It can be managed by front-desk or sales staff, making its contribution margin (revenue minus product cost, with no additional clinical labor) higher than its gross margin alone suggests.

Membership models: predictable recurring revenue

Med spa memberships — typically monthly subscriptions ($99–$299 per month) that include a set number of treatment credits, product discounts and priority scheduling — are a growing revenue category. The model transfers the injectables retention economics into a contractual framework. A member who pays $199 per month for 12 months generates $2,388 in annual revenue regardless of whether they use every credit, and the average member's treatment volume tends to increase as they attempt to "use up" their credits.

Membership models change the financial structure of a clinic in three ways:

• Revenue predictability. Monthly recurring revenue (MRR) from memberships is less sensitive to seasonal dips in treatment demand. A clinic with 200 members at $199/month has $39,800 in MRR that does not depend on new-patient bookings.
• Retention stickiness. Members who cancel a subscription must actively leave. Non-members who simply do not book again are considered attrition. AmSpa survey data indicates that member patients have a 12-month retention rate of 75–85%, compared with 40–55% for non-member treatment-only patients.
• Capacity utilization. Membership credits that go unused represent revenue without corresponding treatment cost — essentially pure margin. Credits that are used fill appointment slots that might otherwise be empty, improving provider utilization.

The retention-rate differential between members and non-members is a clinic-level observation, not an independently controlled study. Selection effects likely play a role: patients who choose a membership may be more engaged and retention-prone regardless of the membership structure.

Ancillary and wellness services

IV vitamin therapy, intramuscular vitamin injections (often vitamin B12, vitamin D or glutathione), hormone-replacement therapy consultations, medical-weight-loss programs and sexual-health services form a smaller but growing revenue category. These services typically carry gross margins of 50–70% depending on product cost and the clinician time required. IV therapy in particular has drawn attention for its high per-treatment revenue ($150–$350 per bag) relative to the cost of fluids and electrolytes, though the service is labor-intensive (nursing time per session) and requires appropriate medical supervision.

The competitive landscape for ancillary services differs from injectables and devices. Many of these services are also offered by wellness clinics, hydration bars, primary-care practices and direct-to-consumer telehealth companies. A med spa's advantage lies in having existing clinical staff, a facility and a patient base who already trust the clinic for other services — but the services themselves are not proprietary.

Patient acquisition costs and retention economics

Revenue per stream is only half of the economic picture. Patient acquisition cost (PAC) — the marketing and sales expense required to bring one new patient through the door — determines how profitable each stream actually becomes.

Industry estimates for med spa patient acquisition cost range widely, from $75–$150 for a patient acquired through in-clinic referral or an existing patient's word-of-mouth, to $200–$500 for a patient acquired through paid digital advertising (Google Ads, Instagram, Facebook). These estimates are reported by practice-management consultants and marketing agencies serving the aesthetics space; no independently verified national average exists because acquisition cost varies dramatically by market, channel, brand recognition and service mix.

The retention economics of injectables explain why acquisition cost is tolerable: a patient acquired at $300 who returns 2.8 times per year at $500 per visit generates $1,400 in annual revenue. Over three years, assuming a 60% annual retention rate typical for non-members, that patient produces approximately $2,500 in cumulative revenue at an acquisition cost of $300 — a roughly 8:1 ratio of lifetime value to acquisition cost.

Membership models improve that ratio. A member acquired at the same $300 cost who stays 18 months at $199/month produces $3,282 in revenue at a lower churn rate. The lifetime-value difference is the central argument for membership adoption.

How financing changes the economics

Patient financing — through third-party lenders such as CareCredit, Alphaeon Credit, Cherry or PatientFi — allows med spas to offer treatment packages with monthly payments rather than requiring full payment at the time of service. Financing increases conversion rates on high-ticket procedures (laser packages, multiple-syringe filler treatments, surgical-adjacent services) by removing the single-payment barrier.

The trade-off is that financing partners charge the clinic a discount fee, typically 3–6% of the financed amount, and the clinic does not receive full payment until the treatment is completed and the financing is approved. For a $3,000 laser package financed at 0% APR for 12 months, the clinic may net approximately $2,850 after the financing fee — a 5% discount for access to a patient who would not otherwise have booked the procedure.

Financing also shifts the timing of revenue recognition. A clinic that collects full payment at the time of service has immediate cash flow. A clinic that finances collects over time. For cash-constrained clinics, this timing difference matters more than the discount percentage.

Consolidation and PE rollups

The most significant structural change in med spa economics in the past five years has been the entry of private equity (PE) capital through platform acquisitions and rollup strategies. Firms backed by PE capital acquire independent med spas regionally or nationally, consolidate operations, centralize administrative functions and seek to expand margins through scale.

PE-backed platforms in the aesthetics space include companies such as AMMD Holdings (backed by Pharos Capital), The Now (backed by General Atlantic), Restore Hyper Wellness (which has raised significant growth capital), and various regional platforms. These are named examples; inclusion here does not constitute an endorsement or a recommendation.

The rollup thesis relies on several assumptions:

• Centralized overhead. Marketing, HR, billing, purchasing and compliance can be managed from a central office, reducing per-location administrative cost by an estimated 15–30% according to operator-reported projections in PE marketing materials and practice-management case studies. This figure is an estimate reported by operators, not an independently verified average.
• Purchasing power. A multi-location operator buying 5,000 syringes of filler per quarter can negotiate pricing that a single-location clinic buying 100 syringes cannot. Wholesale discounts for multi-location purchasers are typical in the injectables supply chain, though specific pricing is proprietary.
• Brand and cross-sell. A patient who visits one location may be routed to another location in another city if they travel, or may be cross-sold into additional services available at the parent company's other brands.
• Valuation arbitrage. A PE firm can acquire a clinic at 4–6x EBITDA and, after scaling to 20–50 locations, sell the combined platform at 8–12x EBITDA to a larger PE firm or strategic buyer. The multiple expansion is the return mechanism, not the clinic's operating cash flow alone.

The consolidation wave is not uniform. The American Society of Plastic Surgeons and the Aesthetics Conference have both noted in their industry-outlook materials that independent single-location med spas remain the majority of operators by count, though the PE-backed segment has captured an outsized share of revenue growth and transaction volume since 2020.

One limitation of the rollup thesis is that med spa economics are local. A clinic's margins depend on its market's demographic profile, competitive density, regulatory environment and provider availability. A centralized purchasing contract cannot change local rent or local wage rates. Some PE-backed platforms have struggled with provider retention after acquisition, particularly when the acquired clinic's lead injector or medical director leaves after a non-compete period expires.

The Wall Street Journal reported in 2023 — and the Financial Times subsequently confirmed in a 2024 analysis — that several PE-backed aesthetics platforms have experienced higher-than-expected clinician turnover and lower same-store sales growth than the initial investment thesis projected. These are media-reported observations, not systematic findings from a controlled study.

What the economics do not capture

Revenue per stream, gross margin and retention rates describe a clinic's financial profile in aggregated terms. They do not capture:

• Regulatory risk. State-by-state variation in ownership rules, supervision requirements and scope-of-practice laws affects which revenue models are legally available. A membership model that is straightforward in Florida may require a different legal structure in California, where the Medical Board requires medical procedures to be performed only in physician-owned practices.
• Provider dependency. An injectables-heavy clinic whose lead injector leaves may lose 30–50% of its revenue within 90 days, regardless of its membership base or retail penetration.
• Pricing pressure. As the number of med spas per capita grows in dense metro areas, downward pricing pressure on injectables and laser treatments has been reported by practice-management consultants. Whether this represents a long-term trend or a local-market phenomenon is not yet settled.
• Insurance and reimbursement. A small but growing number of med spas are incorporating medically necessary services (treatment of hyperhidrosis with neuromodulators, scar revision, rosacea laser therapy) that may be eligible for insurance reimbursement. This introduces a different billing and compliance infrastructure that most elective-aesthetics practices do not maintain.

The bottom line

The med spa industry's revenue structure is not complex, but its economics are often overstated. Injectables produce high gross margins (70–80%) and drive the majority of profit. Memberships improve retention predictability. Retail products extend patient relationships between visits. PE rollups are a financial engineering strategy applied to these fundamentals — they do not change the per-unit economics of a single injection or a single laser pulse.

For a clinic owner evaluating revenue strategy, the relevant comparison is not med spa versus med spa. It is the marginal return on a specific dollar: should the next dollar go toward marketing for new injectables patients, building a membership program, expanding retail inventory or acquiring a device? The answer depends on the clinic's current retention rate, capacity utilization and local competitive position — not on a national average.